Why are some individuals resistant to the cardioprotective effects of aspirin? Could it be thromboxane A2?
نویسندگان
چکیده
It has been slightly more than 100 years since the synthesis, development, and commercialization of acetylsalicylic acid, the most widely consumed drug in the world. It is estimated that 35 000 kg are consumed daily in the United States and 6000 kg in the UK.1 Who would have ever thought that this widely consumed drug would achieve significant uses other than as an analgesic, antipyretic, and anti-inflammatory. The first report of a possible antithrombotic effect of aspirin appeared in 1953 in the Mississippi Valley Medical Journal.2 Dr Craven noticed that the patients who took Aspergum had a tendency to bleed more easily. He concluded that aspirin must be thinning the blood and because thrombosis of the coronary arteries led to myocardial infarction, if his patients took aspirin, they might be less prone to experiencing a myocardial infarction.
منابع مشابه
Thromboxane synthetase inhibitors reduce infarct size by a platelet-dependent, aspirin-sensitive mechanism.
Platelets are suggested to exacerbate ischemia-induced myocardial injury, which has led to the study of various antiplatelet therapies including thromboxane synthetase inhibitors (TXSI). Two such agents, benzylimidazole and OKY-046, reduce infarct size commensurate with a diminution in serum thromboxane B2 formation in anesthetized dogs subjected to 90 minutes of coronary artery occlusion follo...
متن کاملProgress review: the relationship between dose of aspirin, side-effects and antithrombotic effectiveness.
CLINICAL TRIALS over the last decade have demonstrated that aspirin is an effective antithrombotic agent. The antithrombotic effect of aspirin has been attributed to its inhibition of platelet function. Aspirin irreversibly inhibits the enzyme cyclo-oxygenase which in the platelet is responsible for the conversion of arachidonic acid to thromboxane A2 and in vascular wall cells is responsible f...
متن کاملOverexpression of the multidrug resistance protein-4 transporter in patients undergoing coronary artery bypass graft surgery a cause of aspirin resistance?
Millions of people take aspirin every day for the prevention of atherothrombotic cardiovascular events. Aspirin inhibits thrombus formation by irreversibly inactivating the cyclooxygenase (COX)-1 enzyme in platelets, thereby blocking platelet production of thromboxane A2, a potent vasoconstrictor and platelet agonist (1). Multiple studies have reported that in some individuals the effectiveness...
متن کاملAspirin and clopidogrel: efficacy, safety, and the issue of drug resistance.
Aspirin and the thienopyridines ticlopidine and clopidogrel are antiplatelet agents that display good antithrombotic activity. In the past few years, the concept of aspirin resistance has been largely emphasized in the medical literature, although its definition is still uncertain. I suggest that "aspirin-resistant" should be considered as a description for those individuals in whom aspirin fai...
متن کاملPhysiological concentrations of epinephrine potentiate thromboxane A2 release from platelets in the isolated rat heart.
The isolated rat heart perfused with washed platelets was used as a model to examine platelet-vessel wall interactions. Release of prostacyclin and thromboxane A2 was measured, using a cascade of smooth muscle bioassay tissues or radioimmunoassays of the stable hydration products. In hearts perfused with rabbit or human platelets, injection of sodium arachidonate caused release of both prostacy...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Circulation
دوره 105 14 شماره
صفحات -
تاریخ انتشار 2002